Jenburkt Pharmaceuticals Ltd (BOM:524731) Stock Price, Trades & News

Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	21.51
Equity-to-Asset	0.87
Debt-to-Equity	0.01
Debt-to-EBITDA	0.05
Interest Coverage	87.95
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	11.42	Distress Grey Safe
Beneish M-Score	-2.18	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

4/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.6
	3-Year EBITDA Growth Rate	13.5
	3-Year EPS without NRI Growth Rate	16.8
	3-Year FCF Growth Rate	-3.9
	3-Year Book Growth Rate	17.2

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	61.62
	9-Day RSI	52.82
	14-Day RSI	49.13
	3-1 Month Momentum %	6.9
	6-1 Month Momentum %	1.07
	12-1 Month Momentum %	-12.69

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.11
	Quick Ratio	3.52
	Cash Ratio	2.31
	Days Inventory	123.03
	Days Sales Outstanding	48.92
	Days Payable	97.09

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.65
	Dividend Payout Ratio	0.21
	3-Year Dividend Growth Rate	14.5
	Forward Dividend Yield %	1.9
	5-Year Yield-on-Cost %	1.65
	Shareholder Yield %	1.91

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	80.84
	Operating Margin %	24.08
	Net Margin %	20.59
	EBITDA Margin %	29.68
	FCF Margin %	7.59
	OCF Margin %	15.72
	ROE %	18.89
	ROA %	16.51
	ROIC %	17.81
	3-Year ROIIC %	11.29
	ROC (Joel Greenblatt) %	59.49
	ROCE %	24.8
	Years of Profitability over Past 10-Year	10

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	13.42
	Forward PE Ratio	11.82
	PE Ratio without NRI	12.31
	Shiller PE Ratio	17.85
	Price-to-Owner-Earnings	11.12
	PEG Ratio	0.76
	PS Ratio	2.76
	PB Ratio	2.36
	Price-to-Tangible-Book	2.45
	Price-to-Free-Cash-Flow	36.41
	Price-to-Operating-Cash-Flow	17.58
	EV-to-EBIT	9.16
	EV-to-EBITDA	8.58
	EV-to-Revenue	2.55
	EV-to-FCF	32.24
	Price-to-GF-Value	0.97
	Price-to-Projected-FCF	1.57
	Price-to-DCF (Earnings Based)	0.89
	Price-to-DCF (FCF Based)	4.05
	Price-to-Median-PS-Value	1.27
	Price-to-Peter-Lynch-Fair-Value	0.89
	Price-to-Graham-Number	1.18
	Price-to-Net-Current-Asset-Value	7.28
	Price-to-Net-Cash	19.61
	Earnings Yield (Greenblatt) %	10.93
	FCF Yield %	2.67
	Forward Rate of Return (Yacktman) %	18.4

GF Value™: ₹1120.42

BOM:524731

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 524731. Try a 7-Day Free Trial to check it out.

Jenburkt Pharmaceuticals Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Jenburkt Pharmaceuticals Ltd Stock Events

Financials Calendars

	Event	Date	Price (₹)
	INR 20.700000 Cash Dividend	2026-08-28	In 24 days
	INR 18.000000 Cash Dividend	2025-07-11	1,385.70 (-1.02%)

Show

Entries

Press Release

	Subject	Date
No Press Release

Articles on Jenburkt Pharmaceuticals Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.